Rosuvast 20 mg

Rosuvastatin 20 mg

Active liver disease, elevated LFTs
Pregnancy, lactation

Nonserious and reversible cognitive side effects may occur
Increased blood sugar and glycosylated hemoglobin (HbA1c) levels reported with statin intake; in some instances these increases may exceed the threshold for the diagnosis of diabetes mellitus
Use caution in patients who consume large amounts of ethanol or have a history of liver disease
Interrupt therapy if serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment
Measure liver enzymes before initiating and if signs or symptoms of liver injury occur
Consider lower initial dose (5 mg qDay) in patients with risk of myopathy
Increased risk of rhabdomyolysis, especially at highest approved dose of 40 mg/day; reserve highest dose only for patients who fail to achieve desired cholesterol level at 20 mg/day
Use 5 mg/day starting dose in people of Asian ancestry, who may build up higher drug levels and be at higher risk of myopathy
Rare reports of immune-mediated necrotizing myopathy (IMNM), characterized by increased serum creatine kinase that persists despite discontinuing statin
Discontinue if CK levels are markedly elevated
Hematuria and proteinuria reported without decrease in renal function; consider dosage reduction if unexplained hematuria and proteinuria persists
Rule out secondary causes of hyperlipidemia prior to initiating therapy

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Rosuvast 20 mg only for the indication prescribed.